← Leaderboards
Kevin James Horgan
Soligenix, Inc.
$1,337,803
Attributed
$1,337,803
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $537.8K · FY2010–12$1M$750K$500K$250K$0
'10
'11
'12
Funding mix
By agency
FDA$887,803 · 1
NIH$450,000 · 2
By mechanism
R01$887,803 · 1
R43$450,000 · 2
Top collaborators
No co-investigators on record.
Most similar at Soligenix, Inc.
Same institution · by research overlap
- Thomas Rivenburg$7,041,180
- Christopher Joseph Schaber$954,020
- Oreola Donini$1,916,410
Others in their field
Top investigators on “Oral”
- Daniel R Kuritzkes · Brigham And Women'S Hospital$236,409,338
- Judith S. Currier · University Of California Los Angeles$134,347,732
- Constance Ann Benson · University Of California, San Diego$123,741,444
- Wafaa M. El-Sadr · Columbia University Health Sciences$92,413,650
- Myron S Cohen · Family Health International$91,263,426
- Robert A Wood · Johns Hopkins University$57,641,510
Research focus
OralDoseGraft-Vs-Host DiseasePlacebo ControlFutureAcuteDrug FormulationsGlucocorticoidsPharmaceutical PreparationsBiological AvailabilityBeclomethasoneGastrointestinalBoneBody SystemApplications GrantsBlindedClinically SignificantAnimal RuleAdverse EffectsChronic Graft Versus Host DiseaseChronicBeclomethasone DipropionateCessation Of LifeCanis Familiaris
Grant awards (5)
Beclomethasone post exposure therapy for gastrointestinal acute radiation syndrom$300,000
R43 · FY2012 · AI · contact PI
IND 20212 (03-25-99) PHASE 2: ORBEC (ORAL BDP)-PATIENTS WITH CHRONIC GVHD$150,000
R43 · FY2012 · CA · contact PI
IND 20212 (03-25-99) PHASE 3: ORBEC (ORAL BDP) -PATIENTS WITH GI GVHD-FDA-11-12-0$87,803
R01 · FY2012 · FD · contact PI
IND 20212 (03-25-99) PHASE 3: ORBEC (ORAL BDP) -PATIENTS WITH GI GVHD-FDA-11-12-0$400,000
R01 · FY2011 · FD · contact PI
IND 20212 (03-25-99) PHASE 3: ORBEC (ORAL BDP) -PATIENTS WITH GI GVHD-FDA-11-12-0$400,000
R01 · FY2010 · FD · contact PI